drugset / Trial / NCT03589313
Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.
NaSingle-groupOpen-labelTreatment
Summary
This clinical study is a Phase I, open-label, single-center study designed to evaluate the pharmacokinetics profile of a single oral dose of GLPG3067 in adult male subjects with cystic fibrosis in fed state.
Timeline
- Start
- 2018-02-12
- Primary completion
- 2018-03-26
- Completion
- 2018-03-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Navocaftor | Small molecule | — | Oral |